

OMNISENSE 7000S

YOUR EDGE IN THE FIGHT AGAINST OSTEOPOROSIS



 **Sunlight**
Technology solutions at the point of care

Innovative

OMNIPATH™ TECHNOLOGY INNOVATIVE

FINALLY, BONE STRENGTH ASSESSMENT YOU CAN RELY ON

Sunlight's innovative and patented axial transmission technology, Omnipath™, uniquely measures Speed of Sound waves propagating along the bone's maximal strength axis.

OMNIPATH'S AXIAL TRANSMISSION TECHNOLOGY

- Accurate
- Precise
- Eliminates soft tissue effects
- Comprehensive bone strength assessment

THERE IS MORE TO BONE THAN DENSITY

Omnipath's unique Speed of Sound measurements reflect multiple bone properties for a comprehensive assessment:

- Bone Mineral Density
- Elasticity
- Cortical thickness
- Micro-architecture



Omnipath™

"Along the bone" measurements,
eliminate soft tissue effects enabling
a more accurate diagnosis



Measurable

MULTI-SITE MEASURABLE

GETTING THE WHOLE PICTURE

As osteoporosis strikes, it affects the skeletal system at varying degrees and rates causing weakness in some bones while others remain healthy.

Data shows that by providing an overall view of the skeleton, the option of multi-site testing results in higher sensitivity and more accurate fracture discrimination.^{1,2}

MONITORING RESPONSE TO TREATMENT

Various bones may respond to treatment differently or at different speeds. The multi-site option allows you the ability to monitor even small changes following a relatively short treatment period.

OMNISENSE MULTI-SITE - A MEASURABLE ADVANTAGE

Omnisense's unique probe technology is the only one of its kind on the market today. By enabling multi-site measurements, the Omnisense probe system provides you with greater diagnostic ability and enhanced measurement flexibility.

OSTEOPOROSIS RISK INDEX

Sunlight's exclusive Osteoporosis Risk Index (ORI) combines results obtained from paired skeletal sites into a single value that better reflects overall skeletal status.



Radius
a common
atraumatic
fracture site




Phalanx
radius & phalanx
a powerful
combination



Tibia
treatment
monitoring site



Metatarsal
weight bearing
bone



7000S

OMNISENSE

SETTING THE STANDARD IN BONE STRENGTH ASSESSMENT

Proven

CLINICAL RESULTS

PROVEN

An impressive body of clinical evidence supports the efficacy of Omnisense. The collected data demonstrate excellent precision, fracture discrimination and prediction abilities as well as high sensitivity to bone changes caused by treatment or metabolic diseases.

ACCURACY


Comparison studies between Omnisense and DXA of fractured and non-fractured subjects, demonstrate Omnisense's enhanced capability to correctly classify osteoporotic patients (high sensitivity).³⁻⁷

HIP FRACTURE PREDICTION

A number of clinical studies substantiate that Omnisense measurements at the Distal 1/3 Radius and phalanx reliably predict hip fractures.³⁻⁷

MONITORING BONE CHANGES

Omnisense monitors bone changes due to bone related disorders and in response to treatment.



*"The SOS measured by Omnisense has a precision error low enough in comparison with the expected annual change in a patient's measurement to make it suitable for monitoring bone changes which occur in the early years following menopause."*⁸

WHO COMPLIANT

Omnisense results are compatible with World Health Organization criteria for osteoporosis diagnosis. Results are automatically compared to a selectable built-in reference database and are expressed as T-Scores and Z-Scores.

RESULTS YOU CAN TRUST

- Accurate
- High Precision (0.4% CV)
- Monitors bone changes
- Fracture prediction
- Compatible with WHO criteria

- Easy to read colored graph
- Patient measurement history
- Patient information
- T and Z Score results
- Space for comments and recommendations

SPECIFICATIONS

| | |
|--------------------------------|---|
| Technology | Quantitative ultrasound |
| Measured parameter | Axially-transmitted speed of sound (SOS) |
| Precision | 0.40-0.81% in vivo precision, depending on site |
| Accuracy | 0.25-0.50% instrumental accuracy, depending on probe |
| Scan time | Less than 1 minute per skeletal site |
| Duration of examination | Less than 5 minutes |
| Probe | Proprietary multi-transducer ultrasound probes. Center frequency 1.25 MHz |
| Reference database | Site and application-specific databases |
| Regulations | IEC 601-1; IEC 601-1-2, class B; FCC p.15 class B |
| Power | 100-240 Vac~50-60Hz |
| Size (WxHxD) | 39cm x 13cm x 33cm (excluding probe holder and monitor) |
| Weight | 5.9 kg (excluding monitor) |

Specifications subject to change without prior notice. Sunlight Omnisense is a trademark of Sunlight Medical Ltd. Other product names are trademarks of their respective holders.

ABOUT SUNLIGHT

Sunlight Medical Ltd. is an international company with offices in the USA, Germany, Israel and China. Sunlight develops, manufactures and markets advanced, high technology medical devices for the use in primary care facilities and hospitals.

Sunlight's mission is to become the leading provider of technology-intensive solutions for primary care.

Founded in 1995, Sunlight Medical Ltd. has already become a major player in the medical device industry. As a market driven company using cutting edge technology, Sunlight provides innovative, easy to use products for various practices including family doctors, gynecologists, pediatricians and endocrinologists.

The company adheres to the highest scientific and quality standards. Sunlight is ISO 9001 / EN46001 compliant, and is CE 0344 certified.

REFERENCES

- 1 Hans, D. et al., "Does Combining the Results from Multiple Bone Sites Measured by a New Quantitative Ultrasound Device Improve Discrimination of Hip Fracture?" (abstract) *Journal of Bone and Mineral Research*, 1999, vol. 14, No. 4.
- 2 Barkman et al., "A New Method for Quantitative Ultrasound Measurements at Multiple Skeletal Sites First Results of Precision and Fracture Discrimination," *J. Clinical Densitometry* vol 3 no. 1, 1-7, spring 2000.
- 3 Knapp et al. "Multiple Site Ultrasound Measurements Predict Vertebral Fractures in Postmenopausal Women" (abstract), presented at the ASBMR 21st Annual Meeting in St. Louis, MI, USA, September 1999.
- 4 Knapp et al. "Ultrasound Measurements at the Radius Predict Wrist Fractures in Postmenopausal Women" (abstract), presented at the Annual Meeting of the Bone and Tooth Society in Bristol, UK, June 1999.
- 5 Knapp, K et al. "Preliminary Results Of The Sunlight Omnisense Bone Sonometer: In-Vivo And In-Vitro Precision And Correlation With Dxa." (abstract), presented at the ASBMR-IBMS 2nd Joint Meeting, California, USA, December 1998.
- 6 Weiss M, Ben Shlomo A, Hagag P, Ish-Shalom S. "Discrimination Of Proximal Hip Fracture Measurement At The Radius." *Osteoporosis Int*, 2000, 11:411-416.
- 7 Bouxsein, ML et al., "Prediction of Femoral Failure Load from Femoral BMD and Ultrasonic Velocity at the Femur, Radius and Phalanx" (abstract), presented at the ASBMR 21st Annual Meeting in St. Louis, MI, USA, September 1999.
- 8 United States. Dept. of Health and Human Services. P990035. Washington: Food and Drug Administration, 2000.
- 9 Weiss et al. "Effect of Estrogen Replacement Therapy on Speed of Sound at Multiple Skeletal Sites." *Maturitas*, 35 (2000) 237-243.



Sunlight Medical Ltd.
5 Tuval Street
Tel Aviv, 61251, Israel
Tel: (972)3-5620606
Fax: (972)3-5620607
e-mail: info@sunlightnet.com

Sunlight Medical Inc.
100 Davidson Avenue, Suite 108
Somerset, NJ 08873, USA
Tel: (1)732-560-8770
Fax: (1)732-560-9462
Toll Free: 1-800-750-6011
e-mail: info@sunlightnet.com

Sunlight Medical (Deutschland) GmbH
Grüner-Turm-Strasse 16, D-88212
Ravensburg, Germany
Fon: (49)751-363-6230
Fax: (49)751-363-6239
Toll Free: 0180-974-9099
e-mail: yfat@sunlightnet.com

Sunlight Medical Ltd.
Shanghai Representative Office
555 Nan Chang Road, Building
No. B, Room 2003 P.O. Box 200031,
Shanghai, China
Mobile: 86-13801682379
e-mail: yuqi@sunlightnet.com